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Aims Our aim was to evaluate the invasive haemodynamic indices of high-risk symptomatic patients presenting with ‘paradox-
ical’ low-flow, low-gradient, severe aortic stenosis (AS) (PLF-LG) and low-flow, low-gradient severe AS (LEF-LG) and to
compare clinical outcomes following transcatheter aortic valve implantation (TAVI) among these challenging AS sub-
groups.
Methods
and results
Of534symptomaticpatientsundergoingTAVI,385hadafull pre-procedural rightand leftheartcatheterization.Atotalof208
patients had high-gradient severe AS [HGAS; mean gradient (MG)≥40 mmHg], 85 had PLF-LG [MG ≤ 40 mmHg, indexed
aortic valve area [iAVA]≤0.6 cm2 m22, stroke volume index≤35 mL/m2, ejection fraction (EF)≥50%], and 61 had LEF-
LG (MG ≤ 40 mmHg, iAVA ≤0.6 cm2 m22, EF ≤40%). Compared with HGAS, PLF-LG and LEF-LG had higher systemic
vascular resistances (HGAS: 1912+ 654 vs. PLF-LG: 2006+ 586 vs. LEF-LG: 2216+ 765 dyne s m25, P ¼ 0.007) but
lower valvulo-arterial impedances (HGAS: 7.8+ 2.7 vs. PLF-LG: 6.9+1.9 vs. LEF-LG: 7.7+ 2.5 mmHg mL21 m22,
P ¼ 0.027). At 30 days, no differences in cardiac death (6.5 vs. 4.9 vs. 6.6%, P ¼ 0.90) or death (8.4 vs. 6.1 vs. 6.6%,
P ¼ 0.88) were observed among HGAS, PLF-LG, and LEF-LG groups, respectively. At 1 year, New York Heart Associ-
ation functional improvement occurred in most surviving patients (HGAS: 69.2% vs. PLF-LG: 71.7% vs. LEF-LG: 89.3%,
P ¼ 0.09) and no significant differences in overall mortality were observed (17.6 vs. 20.5 vs. 24.5%, P ¼ 0.67). Compared
with HGAS, LEF-LG had a higher 1 year cardiac mortality (adjusted hazard ratio 2.45, 95% confidence interval 1.04–5.75,
P ¼ 0.04).
Conclusion TAVI in PLF-LG or LEF-LG patients is associated with overall mortality rates comparable with HGAS patients and all
groups profit symptomatically to a similar extent.
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Introduction
Severe aortic stenosis (AS) is defined by current guidelines as an
aortic valve area (AVA) ,1 cm2 and a mean gradient (MG)
.40 mmHg in the presence of a normal cardiac output.1 The man-
agement of symptomatic patients presenting with an AVA and
gradient pattern discordant with guideline criteria (e.g. MG
≤40 mmHg and AVA ,1 cm2) is controversial, and can occur
among patients with either preserved or low left-ventricular ejection
fraction (LVEF).2– 12 Among patients with a low LVEF (≤40%), the
combination of a low-gradient (≤40 mmHg) and small AVA
(,1 cm2) (LEF-LG) occurs in 5–10% of patients presenting with
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severe AS and is challenging because the prognosis of conservatively
managed patients is dismal, yet perioperative mortality is high among
those undergoing surgical aortic valve replacement (SAVR).4,5,7,11
More recently, a new entity, paradoxical low-flow [LVEF ≥50%,
but stroke volume index (SVI) ≤35 mL/m2], low-gradient
(≤40 mmHg), severe AS (AVA ,1 cm2) (PLF-LG), has been
described and symptomatic patients treated conservatively had a
higher mortality compared with those undergoing SAVR.2,12 Trans-
catheter aortic valve implantation (TAVI) is an alternative treatment
modality for high-risk or inoperable patients with symptomatic
severe AS.13,14 To date, only few data exist on whether patients pre-
senting with symptomatic PLF-LG benefit from TAVI.15,16 Among
patients with LEF-LG, TAVI may be an attractive alternative to
SAVR as it is less invasive,13 LV functional recovery is enhanced
among patients with low EF undergoing TAVI,17 and transcatheter
heart valve prostheses have a superior haemodynamic profile.18
Aortic stenosis is considered a systemic disease and in quantifying
overall disease severity, it is essential to consider the interrelation
between valvular, arterial, and ventricular variables that may contrib-
ute to the pathophysiology and prognosis in patients with AS.19
Therefore, in a high-risk patient population undergoing TAVI, we
sought first, to compare baseline physiological variables using
invasively derived haemodynamic indices among patients with
low-flow, low-gradient severe AS and either preserved or low
LVEF to patients with high-gradient (.40 mmHg) severe AS
(HGAS) and secondly, to compare clinical outcomes among these
three distinct AS subgroups.
Methods
Patient population
This is a retrospective analysis of prospectively collected data within a
dedicated database that includes all patients with severe native-valve AS
[indexed AVA (iAVA)≤0.6 cm2/m2 or MG.40 mmHg], who underwent
TAVI at our institution between August 2007 and August 2012 (n ¼ 534).
All patientsweredeemed inoperableorathigh surgical risk forconvention-
al surgery by a multidisciplinary team consisting of interventional cardiolo-
gists and cardiothoracic surgeons. Included in this study were all
consecutive patients with: (i) symptomatic severe native-valve AS (iAVA
≤0.6 cm2 and/or MG. 40 mmHg); (ii) a full pre-procedural right and
left heart catheterization within 9 months prior to TAVI; and (iii) complete
clinical follow-up data. Figure 1 summarizes the patient flow. The 354
patients comprising the study population were subdivided into the follow-
ing three groups:
Group 1: HGAS (MG .40 mmHg) (n ¼ 208)
Group 2: PLF-LG (iAVA ≤0.6 cm2, MG ≤40 mmHg, SVI ≤35 mL/m2,
LVEF ≥50%) (n ¼ 85)
Group 3: LEF-LG(iAVA≤0.6 cm2, MG≤40 mmHg, LVEF≤40%) (n¼ 61).
The cohort study complies with the Declaration of Helsinki, was
approved by the local Ethics Committee, and all patients provided
informed written consent.
Cardiac catheterization
All patients underwent coronary angiography and right and left heart
catheterization for haemodynamic assessment prior to TAVI. Data
Figure 1 Description of the patient population. TAVI, transcatheter aortic valve implantation; AVA, aortic valve area; RHC, right and left heart
catheterization; LVEF, left-ventricular ejection fraction; SVI, stroke volume index; HGAS, high-gradient severe aortic stenosis (AS) (mean gradient
.40 mmHg); PLF-LG, paradoxical low-flow, low-gradient (LVEF ≥50%, SVI ≤35 mL m22, mean gradient ≤40 mmHg), severe AS (indexed AVA
≤0.6 cm2 m22); LEF-LG, low-flow, low-gradient (LVEF ≤40%, mean gradient ≤40 mmHg), severe AS (indexed AVA ≤0.6 cm2 m22).
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were prospectively entered into a dedicated database. Intracardiac pres-
sures were recorded with fluid-filled catheters connected to pressure
transducers. Coronary artery disease was defined by a ≥50% lumen
diameter narrowing of the left main coronary artery and ≥70% for the
major epicardial arteries. Multi-vessel CAD was defined as either left
main or two or three major epicardial vessel disease.
Cardiac output
Cardiac output was determined using the Fick method and estimated
oxygen consumption (VO2). For calculating Fick cardiac output, systemic
arterial and pulmonary arterial oxygen saturation, and haemoglobin were
measured directly. The Krakau formula, an equation incorporating both
body surface area and age, was the standard equation used for VO2 esti-
mation.20 Stroke volume (SV) was calculated in all patients as the CO
divided by the heart rate (HR) and was indexed to BSA for calculation
of the SVI.
Aortic stenosis severity
Left-ventricular pressures were directly measured using fluid-filled,
single-lumen pigtail catheters attached to pressure transducers.
Aortic valve gradients were measured in all patients by pullback tech-
nique from the left ventricle to the ascending aorta. Peak-to-peak
gradient was calculated as the difference between the LV systolic
pressure (LVSP) and the aortic systolic arterial pressure. Mean gradi-
ent, represented by the area under the curve, was digitally calculated
by the device software (Schwarzer Systems, Munich, Germany) by
superimposing pressure recordings from three consecutive beats
for patients in sinus rhythm and five consecutive beats for patients
in atrial fibrillation. AVA was derived from the Gorlin equation and
calculated as AVA = (CO/SEP ∗ HR)/44.3√DPm, CO indicating
cardiac output; HR, heart rate; SEP, systolic ejection period; and
DPm, mean gradient. Valvular resistance (VR) was calculated as
VR = (DPm ∗ HR ∗ SEP/CO) ∗ 1.33.
Arterial afterload
Systolic arterial pressure (SAP) and diastolic arterial pressure (DAP)
were measured invasively and mean arterial pressure (MAP) was
calculated as MAP = DAP+ 1/3(SAP −DAP). Systemic arterial
compliance (SAC) was calculated as the ratio of the SVI to the pulse
pressure (SAP-DAP): SAC = (SVI)/SAP −DAP.21 Systemic vascular
resistance (SVR) was calculated using the formula SVR = [(MAP−
RAm) ∗ 80]/[CO] with RAm indicating the mean right atrial pressure.
Global afterload
Valvuloarterial impedance (Zva), ameasureof the global afterload impact-
ing on the left ventricle (i.e. valvular + arterial), was calculated using the
formula of Briand et al21: Zva = LVSP/SVI, where LVSP is the LV systolic
pressure.
Left-ventricular systolic function
Left-ventricular ejection fraction was assessed before TAVI in all patients
with transthoracic echocardiography (TTE) using the biplane Simpson
method and among 330/354 (93%) patients at the time of LV angiography
in the right anterior oblique projection. The remaining 24/354 (7%) did
not undergo LV angiography because of renal impairment. For this ana-
lysis, LVEF calculated at the time of LV angiography was used for calcula-
tions and statistical analysis unless not performed, in which case the LVEF
was calculated from the most recent echocardiogram (n ¼ 24) per-
formed around the time of cardiac catheterization. In case of a disagree-
ment among these methods, the reviewing cardiologist selected the value
that appeared the most representative.
Right heart pressures
Pulmonary hypertension (PH) was defined as a mean pulmonary artery
(PA) pressure≥25 mmHg and was subdivided into pre-capillary PH [left-
ventricular end-diastolic pressure (LVEDP) ≤15 mmHg] and post-
capillary PH (LVEDP .15 mmHg).
Transcatheter aortic valve implantation
procedure
Transcatheter aortic valve implantation was performed using standard
techniques as previously described.22 Vascular access was transfemoral
using the Medtronic CoreValve Revalving System (MCRS) (Medtronic,
Inc., Minneapolis, MN, USA) or the Edwards SAPIEN valve (ESV)
(Edwards Lifesciences, Irvine, CA, USA), transapical for the ESV or
the self-expanding Symetis ACURATE TATM valve (SA) (Symetis Inc.,
Switzerland) or trans-subclavian using the MCRS.
Clinical follow-up
Adverse events were assessed in hospital, and regular clinical follow-up
was performed at 1, 6, and 12 months by means of a clinical visit or a stan-
dardized telephone interview. All suspected events were adjudicated by
an unblinded clinical event committee comprising a cardiac surgeon and
interventional cardiologist. Baseline clinical and procedural characteris-
tics and all follow-up data were entered into a dedicated database, held
at an academic clinical trials unit (CTU Bern, Bern University Hospital,
Switzerland) responsible for central data audits and maintenance of the
database.
Definitions
Clinical endpoints were defined according to the criteria proposed
by the Valve Academic Research Consortium (VARC).23
Study endpoints
Primary endpoint was all-cause mortality, cardiovascular death, and
major adverse cardiovascular and cerebrovascular events (MACCE)
(composite of all-cause mortality, major stroke, and myocardial infarc-
tion) at 30 days and 1 year. Secondary endpoints included cerebrovascu-
lar events (major stroke, minor stroke, transient ischaemic attack) and
myocardial infarction (MI) at 30 days and 1 year. In addition, bleeding (life-
threatening and major), acute renal failure, access site complications
(major and minor), and the VARC combined safety endpoint were
assessed at 30 days. New York Heart Association (NYHA) functional
class status and Canadian Cardiovascular Society (CCS) angina status
were assessed at baseline and 1-year follow-up. Among patients with
an LVEF ≤40%, LVEF recovery in patients with a low MG (≤40 mmHg;
LEF-LG) was compared with LVEF recovery in patients with a high MG
[.40 mmHg; low-flow, high-gradient patients (LEF-HG)] throughout
1 year post-TAVI using TTE. Finally, we assessed the prevalence and
impact of patient–prosthetic mismatch (PPM) on all-cause mortality
at 1 year.
Statistics
Continuous data are presented as means+ standard deviations (SD),
and categorical variables are depicted as percentages and numbers. Cat-
egorical variables were compared by means of thex2 test (or Fisher’s test
for two group comparisons), and continuous variables were compared
using ANOVA (or unpaired t-test for two group comparisons). Left-
ventricular ejection fraction was compared among LEF-LG and
LEF-HG groups before and after TAVI using the paired-samples T-test.
NYHA and CCS functional status at 1 year was analysed using x2
tests comparing improved vs. not improved survivors across the
three patient groups. Time-to-outcome data are presented using
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Kaplan–Meier curves, with incidence rates calculated from life-tables, at
30 days and 1-year follow-up, respectively. Univariate and inverse prob-
ability treatment weighting (IPTW) adjusted Cox proportional hazards
models were used to derive hazard ratio estimates of clinical
time-to-outcome comparisons between groups (death, cerebrovascular
events, myocardial infarction, and their composites). Univariate Poisson
regression models with robust error variances were used to derive risk
ratio estimates of all other clinical outcome comparisons between
groups. Inverse probability treatment weighting was calculated as the
inverse probability of the group weight from a multinomial regression
with group as response (HGAS, PLF-LG, or LEF-LG), including the base-
line predictors: age, gender, body mass index, previous MI, previous cor-
onary artery bypass grafting, previous percutaneous coronary
intervention (PCI), peripheral vascular disease (PVD), and coronary
artery disease. All P-values and 95% confidence intervals (CIs) are two-
sided. Two-sided P-values , 0.05 were considered statistically signifi-
cant. All analyses were performed with STATA (version 12, StataCorp,
College Station, TX, USA).
Results
Patient characteristics
Baseline characteristics are given in Table 1. Mean age was 82.5+ 5.2
years and significantly more females presented with HGAS com-
pared with LEF-LG. No significant differences were observed in the
proportion of PLF-LG patients presenting with NYHA class III/IV
shortness of breath at baseline compared with HGAS patients (61
vs. 71%, P ¼ 0.13). PLF-LG patients, however, were more likely to
present with CCS class III/IV angina compared with HGAS patients
(24 vs. 10%, P ¼ 0.004). Significantly more patients with LEF-LG
presented in NYHA class III/IV compared with PLF-LG (82 vs. 61%,
P ¼ 0.012). LEF-LG patients had a significantly higher incidence of
previous MI, moderate mitral regurgitation, and logistic EuroSCORE,
compared with both HGAS and PLF-LG. LEF-LG patients also had a
significantly higher rate of coronary artery disease compared with
HGAS and a significantly higher STS score compared with PLF-LG.
Both PLF-LG and LEF-LG groups had significantly higher rates of
multi-vessel coronary artery disease, PVD, previous PCI, and
higher baseline clopidogrel use compared with HGAS patients.
Haemodynamic characteristics
Haemodynamic characteristics are presented in Table 2 and Figure 2.
Median interval between cardiac catheterization and TAVI was 20
days [interquartile range (IQR): 8–40 days]. All patients by definition
had severe AS. PLF-LG patients, however, had a significantly larger
AVA, iAVA, and lower VR compared with both HGAS and LEF-LG
patients. HGAS patients had an overall higher global afterload
(Zva) despite a significantly lower arterial afterload (SVR and SAP)
compared with both PLF-LG and LEF-LG groups because of a
higher valvular load. Conversely, PLF-LG patients had a lower
global afterload despite a significantly higher arterial afterload com-
pared with HGAS patients. LEF-LG patients had a lower systolic ar-
terial pressure (pseudonormalization) yet a significantly higher SVR
compared with both HGAS and PLF-LG groups. In addition,
LEF-LG patients had a significantly higher global afterload compared
with PLF-LG, but not HGAS, patients. Mean LVEF was 53%. Com-
pared with HGAS, PLF-LG patients had a significantly higher LVEF
despite a significantly lower cardiac output. HGAS patients had sig-
nificantly higher LVSP, SV, SVI, CO, and CI values compared with
PLF-LG and LEF-LG groups, although the latter four variables were
all in the low range. Overall, 77% of patients hadpulmonary hyperten-
sion (PH), which was secondary to left-sided heart disease in most
(82%) cases. Incidence of PH was highest among LEF-LG (90%) and
lowest among PLF-LG (70%) patients.
Procedural characteristics
Procedural characteristics are given in Table 3. Mean procedural time
was 77.7+35.7 min. Transfemoral route and Medtronic CoreValve
were used in most cases. More PLF-LG patients had transapical TAVI
comparedwith HGAS. Significantly morepatientswith HGASunder-
went concomitant PCI compared with LEF-LG. Overall VARC device
success was 86%. Main reason for the absence of device success was
post-procedural paravalvular aortic regurgitation ≥2+ but not a
failure to implant the device successfully.
Clinical outcomes
Median follow-up was 370 days (IQR: 43–738 days) and no patients
were lost to follow-up. Event rates with crude and adjusted hazard
ratios (HR) for all major clinical endpoints at 30 days and
12 months are provided in Tables 4 and 5.
Primary endpoint at 30 days
No significant differences in MACCE (10.2 vs. 6.1 vs. 9.9%, P ¼ 0.58),
cardiovascular death (6.5 vs. 4.9 vs. 6.6%, P ¼ 0.90), or all-cause mor-
tality (8.4 vs. 6.1 vs. 9.9%, P ¼ 0.58) were observed at 30 days among
HGAS, PLF-LG, and LEF-LG groups, respectively.
Secondary endpoints at 30 days
No significant differences were observed in cerebrovascular events,
bleeding, acute renal failure, or access site complicationsbetweenany
groups at 30 days (Table 4). Combined VARC safety endpoint was 25,
17.6, and 31.1% (P ¼ 0.17) in HGAS, PLF-LG, and LEF-LG groups,
respectively.
Primary endpoint at 1 year
Survival curves for MACCE, cardiovascular death, and all-cause mor-
tality are shown in Figure 3. No significant differences in unadjusted
rates of MACCE (21.5 vs. 20.5 vs. 25.8%, P ¼ 0.74) and death (17.6
vs. 20.5 vs. 24.5%, P ¼ 0.67) were observed at 12 months among
HGAS, PLF-LG, and LEF-LG groups, respectively. However, com-
paredwith HGAS, a significantly higher rate of cardiovascular mortal-
ity at 12 months was observed among LEF-LG patients [8.6 vs. 22.5%,
hazard ratio (HR) 2.39, 99% CI 1.11–5.15, P ¼ 0.03] and the signifi-
cance remained after adjustment for age, gender, BMI, previous MI,
CABG, PCI, PVD, and coronary artery disease (HR 2.45, 95% CI
1.04–5.75, P ¼ 0.04).
Secondary endpoints at 1 year
No significant differences in cerebrovascular events or MI were
observed at 1-year follow-up between groups.
NYHA and CCS functional status at 1 year
89.3, 71.7, and 69.2% of surviving LEF-LG, PLF-LG, and HGAS
patients, respectively, improved at least one NYHA level at 1 year
C.J. O’Sullivan et al.3440
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Table 1 Baseline clinical characteristics
All patients
(n5 354)
HGAS
(n 5 208)
PLF-LG
(n5 85)
LEF-LG
(n 5 61)
P-value
Demographics
Age (years) 82.5+ 5.2 82.9+ 5.2 82.0+ 5.2 82.0+ 5.0 0.28
Female gender, n (%) 202 (57) 128 (62)a 47 (55) 27 (44)a 0.053
Physical dimensions
Body mass index (kg/m2) 26.6+ 5.2 26.5+ 5.1 27.6+ 5.4b 25.5+ 5.4b 0.048
Body surface area (m2) 1.8+ 0.2 1.8+ 0.2 1.8+ 0.2 1.8+ 0.2 0.67
Cardiac risk factors
Diabetes mellitus, n (%) 101 (29) 55 (26) 27 (32) 19 (31) 0.58
Hypercholesterolaemia, n (%) 224 (63) 126 (61) 57 (67) 41 (67) 0.45
Hypertension, n (%) 298 (84) 174 (84) 73 (86) 51 (84) 0.89
Current smoker, n (%) 36 (10) 23 (11) 7 (8) 6 (10) 0.77
Past medical history
Coronary artery disease, n (%) 209 (59) 111 (53)a 53 (62) 45 (74)a 0.013
Multivessel disease 128 (40) 62 (33)a,c 36 (46)c 30 (54)a 0.008
Previous myocardial infarction, n (%) 52 (15) 19 (9)a 13 (15)b 20 (33)a,b ,0.001
Previous coronary artery bypass graft, n (%) 50 (14) 22 (11) 16 (19) 12 (20) 0.07
Previous percutaneous coronary intervention, n (%) 84 (24) 36 (17)a,c 26 (31)c 22 (36)a 0.002
Previous stroke, n (%) 25 (7) 12 (6) 6 (7) 7 (11) 0.31
Peripheral vascular disease, n (%) 70 (20) 29 (14)a,c 23 (27)c 18 (30)a 0.004
Chronic obstructive pulmonary disease, n (%) 62 (18) 33 (16) 20 (24) 9 (15) 0.25
Renal failure (GFR, 60 mL min21 1.73 m22) 241 (68) 137 (66) 56 (67) 48 (79) 0.17
Valvular disease
Previous valve surgery, n (%) 3 (1) 3 (1) 0 (0) 0 (0) 0.35
Moderate aortic regurgitation,d n (%) 30 (10) 21 (12) 3 (4) 6 (11) 0.18
Moderate mitral regurgitation, n (%) 76 (24) 37 (20)a 14 (18)b 25 (44)a,b ,0.001
Severe mitral regurgitation, n (%) 10 (3) 4 (2) 2 (3) 4 (7) 0.18
Baseline cardiac rhythm
Atrial fibrillation, n (%) 104 (29) 56 (27) 27 (32) 21 (34) 0.45
Symptoms
New York Heart Association (NYHA) Functional Class
NYHA III/IV, n (%) 249 (71) 147 (71) 52 (61)b 50 (82)b 0.024
Canadian Cardiovascular Society (CCS) Angina Status
CCS III/IV, n (%) 49 (14) 21 (10)c 20 (24)c 8 (13) 0.009
Risk assessment
Logistic EuroScore (%) 23.6+ 13.8 20.9+ 12.4a 19.7+ 9.0b 38.0+ 14.7a,b ,0.001
STS score (%)
Mean 7.0+ 5.5 6.9+ 6.2 6.5+ 3.4b 8.2+ 5.2b 0.16
Median (25%–75% IQR) 5.6 (4.0–8.1) 5.3 (3.8–7.8) 5.4 (4.0–8.8) 6.9 (4.6–10.3) 0.016
Medications
Aspirin, n (%) 222 (63) 124 (60) 55 (65) 43 (70) 0.28
Clopidogrel, n (%) 64 (18) 26 (13)a,c 23 (27)c 15 (25)a 0.004
Oral anticoagulation, n (%) 98 (28) 50 (24) 26 (31) 22 (36) 0.15
Laboratory values
Continued
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Table 1 Continued
All patients
(n5 354)
HGAS
(n5 208)
PLF-LG
(n5 85)
LEF-LG
(n5 61)
P-value
B-type natriuretic peptide (pg/mL) 641.0+ 846.6 573.0+ 785.4c, a 272.4+ 287.9 b,c 1283.2+ 1100.3a,b ,0.001
Values are n (%) or mean+ standard deviation with P-values from ANOVAs orcounts (%) with P-values fromx2 tests. STS score was left-skewed and therefore also median (25–75%
interquartile range) with Kruskall–Wallis test and Mann–Whitney U-tests are reported.
STS score, Society for Thoracic Surgeons score.
aSignificant difference between low-flow, low-gradient severe aortic stenosis (LEF-LG) and HGAS groups.
bSignificant differences between patients with PLF-LG and LEF-LG groups.
cSignificant difference between patients with high-gradient severe aortic stenosis (HGAS) and patients with paradoxical low-flow, low-gradient, severe aortic stenosis (PLF-LG)
groups.
dNo patients had severe aortic regurgitation at baseline.
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Table 2 Invasive haemodynamic data
All patients
(n 5 354)
HGAS
(n5 208)
PLF-LG
(n 5 85)
LEF-LG
(n5 61)
P-value
Aortic stenosis severity
Aortic valve area, cm2 0.52+ 0.21 0.47+ 0.21a,b 0.61+ 0.19a,c 0.58+ 0.19b,c ,0.001
Indexed aortic valve area, cm2 m22 0.29+ 0.11 0.26+ 0.11a,b 0.34+ 0.10a,c 0.33+ 0.10b,c ,0.001
Peak-to-peak gradient, mmHg 54.08+ 27.53 67.88+ 23.78a,b 37.71+ 14.97a,c 29.85+ 23.60b,c ,0.001
Mean gradient, mmHg 44.52+ 17.09 55.62+ 12.39a,b 31.05+ 6.58a,c 25.46+ 8.58b,c ,0.001
Valvular resistance, dynes cm25 343.52+ 209.83 426.79+ 226.18a,b 221.95+ 85.71a,c 231.74+ 122.66b,c ,0.001
Systemic vascular load
Systolic arterial pressure, mmHg 135.60+ 29.06 136.56+ 29.52a,b 140.42+ 27.94a,c 125.59+ 27.06b,c 0.007
Diastolic arterial pressure, mmHg 65.97+ 14.25 65.15+ 14.37 66.93+ 13.41 67.44+ 14.96 0.42
Mean arterial pressure 93.92+ 18.55 93.61+ 19.22 96.65+ 17.68 91.18+ 17.12 0.20
Systemic vascular resistance, dynes cm25 1987.30+ 666.96 1912.09+ 654.06a,b 2006.65+ 586.92a,c 2216.78+ 765.05b,c 0.007
Systemic arterial compliance, mL mmHg21 0.43+ 0.19 0.45+ 0.21 0.39+ 0.13 0.43+ 0.19 0.11
LV global afterload
Valvuloarterial impedance, mmHg mL21 m22 7.57+ 2.49 7.80+ 2.67a,b 6.94+ 1.88a,c 7.66+ 2.50b,c 0.027
LV systolic function
Ejection fraction, % 52.65+ 15.78 56.48+ 13.82a,b 60.25+ 6.53a,c 29.02+ 6.73b,c ,0.001
LV systolic pressure, mmHg 189.68+ 35.27 204.43+ 31.46a,b 178.13+ 28.95a,c 155.44+ 24.43b,c ,0.001
LV end diastolic pressure, mmHg 21.38+ 8.02 21.95+ 8.21a,b 18.84+ 7.43a,c 22.98+ 7.42b,c 0.002
Stroke volume, mL 48.11+ 15.16 50.91+ 16.66a,b 47.77+ 9.76a,c 39.02+ 12.23b,c ,0.001
Stroke volume index, mL m22 26.94+ 7.71 28.55+ 8.47a,b 26.63+ 4.73a,c 21.85+ 5.97b,c ,0.001
Cardiac output, L min21 3.69+ 0.96 3.85+ 1.02a,b 3.72+ 0.74a,c 3.11+ 0.79b,c ,0.001
Cardiac index, L min21 m22 2.07+ 0.48 2.16+ 0.51a,b 2.07+ 0.34a,c 1.74+ 0.36b,c ,0.001
Right-sided haemodynamic data
Mean PA pressure, mmHg 33.51+ 11.49 32.62+ 11.58a,b 30.22+ 10.42a,c 40.98+ 9.33b,c ,0.001
Pulmonary hypertension,d n (%) 259 (77) 149 (76)a,b 57 (70)a,c 53 (90)b,c 0.022
Pre-capillary PH, n (%) 47 (14) 25 (13) 15 (19) 7 (12) 0.40
Post-capillary PH, n (%) 212 (63) 124 (63)a,b 42 (52)a,c 46 (78)b,c 0.007
Values are n (%) or mean+ standard deviation.
PA, pulmonary artery; PH, pulmonary hypertension.
aSignificant difference between patients with high-gradient severe aortic stenosis (HGAS) and patients with paradoxical low-flow, low-gradient, severe aortic stenosis (PLF-LG)
groups.
bSignificant difference between low-flow, low-gradient severe aortic stenosis (LEF-LG) and HGAS groups.
cSignificant differences between patients with PLF-LG and LEF-LG group.
dPulmonary hypertension ¼ mean PA pressure ≥25 mmHg.
C.J. O’Sullivan et al.3442
Figure 2 Diagram illustrating the interrelation between the ventricular, valvular, and arterial components among patients with high-gradient,
severe aortic stenosis (AS) (HGAS), ‘paradoxical’ low-flow, low-gradient, severe AS (PLF-LG) and low-flow, low-gradient, severe AS (LEF-LG).
PLF-LG and LEF-LG patients had a significantly higher arterial afterload despite a lower valvulo-arterial impedance (Zva). Values taken from
Table 2. SVR, systemic vascular resistance; SAC, systemic arterial compliance; SAP, systemic arterial blood pressure; MG, mean gradient; iAVA,
indexed aortic valve area; LVEF, left-ventricular ejection fraction; SVI, stroke volume index.
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Table 3 Procedural characteristics
All patients
(n5 354)
HGAS
(n5 208)
PLF-LG
(n5 85)
LEF-LG
(n5 61)
P-value
Access route 0.09
Femoral, n (%) 291 (82) 179 (86)a 64 (75)a 48 (79) 0.07
Apical, n (%) 59 (17) 28 (13)a 20 (24)a 11 (18) 0.11
Subclavian, n (%) 4 (1) 1 (0) 1 (1) 2 (3) 0.19
Valve type 0.59
Medtronic CoreValve, n (%) 200 (56) 119 (57) 43 (51) 38 (62) 0.35
Edwards Sapien valve, n (%) 152 (43) 88 (42) 41 (48) 23 (38) 0.43
Symetis valve, n (%) 2 (1) 1 (0) 1 (1) 0 (0) 0.63
Revascularization 0.07
Concomitant PCI, n (%) 55 (16) 40 (19)b 10 (12) 5 (8)b 0.06
Staged PCI, n (%) 37 (10) 16 (8) 11 (13) 10 (16) 0.10
Procedural specifications 0.49
Device success, n (%) 303 (86) 175 (85) 78 (92) 50 (82) 0.17
No device success: valve in series, n (%) 6 (2) 3 (1) 2 (2) 1 (2) 0.86
No device success: aortic regurgitation ≥grade 2, n (%) 39 (11) 25 (12) 5 (6) 9 (15) 0.18
No device success: access failure, failure of deployment or
retrieval, n (%)
5 (1) 4 (2) 0 (0) 1 (2) 0.44
Values are n (%) or mean+ standard deviation.
PCI, percutaneous coronary intervention.
aSignificant difference between patients with high-gradient severe aortic stenosis (HGAS) and patients with paradoxical low-flow, low-gradient, severe aortic stenosis (PLF-LG)
groups.
bSignificant difference between low-flow, low-gradient severe aortic stenosis (LEF-LG) and HGAS groups.
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(compared with no change or worsened P ¼ 0.09; Figure 4A). All
patients with PLF-LG and LEF-LG improved at least one CCS func-
tional class level at 1 year as did 85% of HGAS patients (Figure 4B).
Transthoracic echocardiography
follow-up among low-flow, low-gradient
and low-flow, high-gradient patients
Baseline and follow-up LVEF among patients with LEF-LG (n ¼ 61)
and the subgroup of patients (n ¼ 34) with low-flow (LVEF ≤
40%), high-gradient (.40 mmHg) (LEF-HG) severe AS are shown
in Figure 5. Compared with baseline, a significant improvement in
LVEF was observedat1-year follow-up amongboth LEF-LG (baseline
LVEF: 28.2+ 5.9% vs. 1-year LVEF: 39.4+13.6%, P ¼ 0.015) and
LEF-HG (31.8+7.2 vs. 50.1+14.2%, P, 0.0001) groups after
TAVI. Compared with LEF-HG, LVEF improvement was less
among LEF-LG patients at 30 days (9.1+10.5 vs. 21.4+11.2%,
P, 0.001) and 1 year (11.2+14.1 vs. 18.3+ 13.0%, P ¼ 0.17),
although differences were significant only at 30 days.
Patient–prosthetic mismatch
Patient–prosthetic mismatch was defined as a post-procedural
indexed AVA≤0.85 cm2 m22 using transthoracic echocardiography.
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Table 4 Clinical outcomes at 30 days and 1-year follow-up
HGAS
(n5 208)
PLF-LG
(n5 85)
LEF-LG
(n5 61)
PLF-LG vs. HGAS LEF-LG vs. HGAS Overall
P-value
HR or RR
(95% CI)
P-value HR or RR
(95% CI)
P-value
30 days follow-up
All cause death,a n (%) 16 (8.4) 5 (6.1) 4 (6.6) 0.78 (0.29–2.13) 0.63 0.86 (0.29–2.57) 0.78 0.88
Cardiovascular death,a n (%) 12 (6.5) 4 (4.9) 4 (6.6) 0.83 (0.27–2.58) 0.75 1.14 (0.37–3.54) 0.82 0.90
Cerebrovascular events
Major Stroke, n (%) 10 (4.9) 1 (1.2) 1 (1.6) 0.24 (0.03–1.90) 0.18 0.34 (0.04–2.63) 0.30 0.26
Minor Stroke, n (%) 1 (0.5) 0 (0.0) 1 (1.6)
Transient ischaemic attack, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Myocardial infarction, n (%) 0 (0.0) 0 (0.0) 1 (1.6)
All cause death, major stroke, or MI,a n
(%)
20 (10.2) 5 (6.1) 6 (9.9) 0.61 (0.23–1.61) 0.32 1.02 (0.41–2.55) 0.96 0.58
Bleeding
Life-threatening, n (%) 35 (16.9) 11 (12.9) 10 (16.4) 0.77 (0.41–1.44) 0.41 0.97 (0.51–1.84) 0.92 0.70
Major, n (%) 58 (28.0) 23 (27.1) 14 (23.0) 0.97 (0.64–1.46) 0.87 0.82 (0.49–1.36) 0.44 0.74
Acute renal failure, n (%) 8 (3.8) 4 (4.7) 1 (1.6) 1.22 (0.38–3.96) 0.74 0.43 (0.05–3.35) 0.42 0.64
Access site complications
Major, n (%) 19 (9.1) 4 (4.7) 7 (11.5) 0.52 (0.18–1.47) 0.22 1.26 (0.55–2.85) 0.59 0.33
Minor, n (%) 26 (12.5) 12 (14.1) 9 (14.8) 1.13 (0.60–2.13) 0.71 1.18 (0.58–2.38) 0.64 0.87
VARC Safety endpoint, n (%) 52 (25.0) 15 (17.6) 19 (31.1) 0.71 (0.42–1.18) 0.19 1.25 (0.80–1.94) 0.33 0.17
1-year follow-up
All cause death,a n (%) 31 (17.6) 14 (20.5) 12 (24.5) 1.13 (0.60–2.12) 0.71 1.36 (0.70–2.64) 0.37 0.67
Cardiovascular death,a n (%) 16 (8.6) 8 (12.3) 11 (22.5) 1.25 (0.53–2.92) 0.61 2.39 (1.11–5.15) 0.03 0.08
Cerebrovascular events
Major stroke, n (%) 12 (6.4) 1 (1.2) 1 (1.6) 0.20 (0.03–1.56) 0.13 0.28 (0.04–2.19) 0.23 0.17
Minor stroke, n (%) 1 (0.5) 0 (0.0) 1 (1.6) 1.00 3.41 (0.21–54.51) 0.39 0.37
Transient ischaemic attack, n (%) 0 (0.0) 2 (4.0) 0 (0.0) 0.08 0.09
Myocardial infarction, n (%) 1 (0.7) 0 (0.0) 1 (1.6) 1.00 3.44 (0.21–54.94) 0.38 0.37
All cause death, major stroke, or MI,a
n (%)
38 (21.5) 14 (20.5) 13 (25.8) 0.89 (0.48–1.65) 0.71 1.20 (0.64–2.25) 0.58 0.74
Depicted are counts (incidence rates %). Hazard ratios (HR) [95% confidence intervals (CI)] from Cox regressions for time-to-event data (death to myocardial infarction). In case of
zero events, only Fisher’s test P-values are reported. Risk ratios (RR) from Poisson regression with robust error variances forotherevent data at 30 days [bleeding to valvular academic
research consortium (VARC) safety endpoint]. Other abbreviations as in Table 1.
aPrimary endpoint components.
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The prevalence of PPM and post-procedural valvular haemodynam-
ics are shown in Table 6. Post-procedural echocardiographic data
were available in 307 out of 354 (87%) patients. Severe and moderate
PPM was observed in 2 and 25% of patients, respectively. No signifi-
cant differences in the incidence of PPM between groups were seen.
In addition, no significant differences in 1 year overall mortality were
observed among patients with and without PPM (Table 7).
Discussion
The main findings can be summarized as follows: first, we confirmed
the presence of PLF-AS using invasive haemodynamic indices among
a high-risk cohort of patients undergoing TAVI. Most PLF-LG patients
were symptomatic, had a high afterload, and the majority demon-
strated functional improvement 1 year following the procedure.Clin-
ical outcomes were similar to HGAS patients. Secondly, only limited
data are available on clinical outcomes among patients with LEF-LG
undergoing TAVI.24– 26 We found that most surviving LEF-LG
patients exhibited functional improvement at 1-year follow-up. A sig-
nificant improvement in LVEF compared with baseline was observed
among LEF-LG patients but the LVEF improvement was less when
compared with LEF-HG patients. Thirdly, despite being at significant-
ly higher surgical risk, patientswith LEF-LGhad overallmortality rates
similar to lower-risk HGAS and PLF-LG patients. LEF-LG patients,
however, were more likely to die from cardiac causes compared
with HGAS patients. Finally, PPM did not appear to impact on
overall mortality rates at 1 year even among LEF-LG patients.
Overall, the majority of patients demonstrated significant functional
improvement following TAVI regardless of AS subtype. Therapeutic
measures aimed at reducing cardiovascular mortality among LEF-LG
patients following TAVI should be identified.
Paradoxical low-flow aortic stenosis
In the present study, patients presenting with PLF-LG were predom-
inantly symptomatic, female, hypertensive octogenarians with a high
incidence of multi-vessel coronary artery disease and pulmonary
hypertension. Herrmann et al.,15 in a post-hoc analysis of the Place-
ment of Aortic Transcatheter Valves (PARTNER) trial, were first
to assess the clinical outcomes of patients with PLF-LG severe AS
(defined using echocardiographic criteria) undergoing TAVI with
the Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA,
USA). Among the cohort with PLF-LG, those undergoing TAVI had
a significantly improved survivalwhencomparedwith patientsunder-
going medical management at 1 year (HR 0.38, 95% CI 0.16–0.87,
P ¼ 0.02). In addition, low flow (SVI ≤ 35 mL m22) was found to
be an independent predictor of mortality in all patient cohorts,
whereas ejection fraction and gradient were not.15 The present
study complements the PARTNER analysis by confirming the pres-
ence of PLF-LG among high-risk patients undergoing TAVI using inva-
sive haemodynamic data. In addition, the latter study did not provide
data on the arterial afterload of patients with PLF-LG severe AS,
which is thought to play a key role in the pathophysiology of
PLF-LG severe AS. We were able to confirm using invasive haemo-
dynamic indices that high-risk PLF-LG patients undergoing TAVI do
indeed have an elevated afterload as reflected by a high systemic vas-
cular resistance and valvuloarterial impedance and low systemic ar-
terial compliance. Furthermore, the PARTNER analysis excluded
patients with severe obstructive coronary artery disease and no
patients received a Medtronic CoreValve both of which were
included in the present analysis. It has previously been reported
that symptomatic patients presenting with features of PLF-LG were
less likely to be referred to SAVR when compared with their high-
gradient counterparts.2,12 One reason for this may be because a
low MG among patients presenting with a normal LVEF is perceived
to imply a non-severe form of AS. However, MG is directly propor-
tional to the square of flow and inversely proportional to the square
of AVA.12 Therefore, even a small reduction in flow can lead to a sub-
stantial reduction in theMG,even thoughLVEFmay remainwithin the
normal range. In the present study, all PLF-LG patients had an LVEF
≥50%, an MG in the mild-to-moderate range, yet all had an
indexed AVA in the severe range suggesting severe AS. In such clinical
scenarios, recent studies have shown that the next important steps
are to ensure that AVA is indexed to body surface area (rule out
small body size) and to assess the flow status.2,12,27 All PLF-LG had
a low-flow pattern as indicated by an SVI ≤35 mL m22. Following
TAVI, the majority demonstrated excellent functional improvement
yet only one quarter of patients underwent revascularization, sug-
gesting that the pre-procedural symptoms were directly related to
the valve stenosis in a majority of cases.
PLF-LG vs. HGAS
Bydefinition, all patients included in this studyhadsevereASdefinedby
an indexed AVA ≤0.6 cm2 m22. Compared with HGAS, however,
PLF-LG patients had a significantly larger valve area indicating a less
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Adjusted primary endpoints at 1-year follow-upa
HGAS
(n 5 208)
PLF-LG
(n5 85)
LEF-LG
(n 5 61)
PLF-LG vs. HGAS LEF-LG vs. HGAS Overall
P-value
HR (95% CI) P-value HR (95% CI) P-value
1-year follow-up
All cause death, n (%) 31 (17.6) 14 (20.5) 12 (24.5) 1.25 (0.65–2.41) 0.50 1.25 (0.59–2.68) 0.56 0.73
Cardiovascular death, n (%) 16 (8.6) 8 (12.3) 11 (22.5) 1.49 (0.62–3.61) 0.37 2.45 (1.04–5.75) 0.04 0.12
All cause death, major
stroke, or MI, n (%)
38 (21.5) 14 (20.5) 13 (25.8) 0.93 (0.50–1.76) 0.83 1.07 (0.53–2.19) 0.85 0.95
Depicted are counts (incidence rates%).
aAdjusted for age, gender, body mass index, previous myocardial infarction, previous coronary artery bypass grafting, previous percutaneous coronary intervention, peripheral
vascular disease and coronary artery disease. Hazard ratios (HR) [95% confidence interval (CI)] from Cox regressions weighted by inverse probability treatment weighting (IPTW).
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severe form of AS, although whether this had clinical implications is
unclear as there were no significant differences in baseline symptoms.
In addition, while the arterial afterload was higher among PLF-LG
patients compared with HGAS, global afterload (Zva) was significantly
lower. At first glance, these findings appear discordant with previous
studies reporting either a similar or smaller sized indexed AVA and a
Figure 3 Kaplan–Meier analysis of major adverse cardiovascular and cerebrovascular events (MACCE; composite of death, major stroke, and
myocardial infarction) at 30 days (A) and 1 year (B), cardiovascular death at 30 days (C ) and 1 year (D), and death at 30 days (E) and 1 year (F)
among the three groups. HGAS, high-gradient, severe aortic stenosis (AS); PLF-LG, paradoxical low-flow, low-gradient, severe AS; LEF-LG,
low-flow, low-gradient, severe AS.
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higher Zva among PLF-LG patients compared with normal flow, high-
gradient patients.2,12 Further analysis reveals, however, that most
HGAS patients (80.3%) included in this study have in fact a low
stroke volume and therefore this group predominantly comprises a
low-flow, high-gradient severe AS patient population. This high preva-
lence of low-flow among HGAS patients is partly explained by the fact
that a minority of these patients (n ¼ 49/208; 24%) had a low LVEF
(,50%). However, even among HGAS patients with a preserved
LVEF (n ¼ 159/208; 76%), low-flow was observed in a majority of
patients (77%). In patients with severe AS and hypertrophied ventri-
cles, an LVEF of 50% may not be entirely normal. In addition, similar
to PLF-LG patients, the HGAS patient population comprised elderly
hypertensive patients with a high prevalence of coronary artery
disease. Therefore, both groups may have had intrinsic myocardial dys-
function caused by a chronically high afterload and/or ischaemic heart
disease resulting in a low-flow state, yet the HGAS group had a much
greater stenosis severity to the extent that despite low-flow, their gra-
dients remained high (.40 mmHg).Therefore, even though thearter-
ial afterload was significantly lower in comparison with PLF-LG
patients, HGAS patients nonetheless had an overall higher global
(valvular + arterial) afterload due predominantly to the valvular com-
ponent. A similar observation was reported in an echocardiographic
study by Dumesnil et al.,28 where low-flow, high-gradient patients
were found to have a smaller indexed AVA (0.3 vs. 0.5 cm2 m22)
Figure 4 Functional clinical outcome. Functional status expressed by New York Heart Association (NYHA) classification (A) and the Canadian
Cardiovascular Society (CCS) angina classification (B) at 1-year follow-up compared with baseline. Very light blue ¼ improved 4 levels, light blue ¼
improved 3 levels: medium blue ¼ improved2 levels; darkblue ¼ improved1 level; green ¼ no change; pink ¼ worsened1 level; red ¼ worsened2
levels.
TAVI and low-gradient aortic stenosis 3447
and a higher Zva (6.0 vs. 5.2 mmHg mL21 m22) compared with
PLF-LG patients.
Low flow, low gradient, low ejection
fraction
LEF-LG occurs in 5–10% of all patients with severe AS.14 These
patients are challenging to manage because they have a dismal prog-
nosis with medical therapy,7 yet have a high perioperative mortality
(up to 22% in a recent series4) undergoing SAVR.4,7 Transcatheter
aortic valve implantation has emerged as an alternative treatment
option in this difficult subgroup but to date, only limited data are
available regarding the feasibility and outcome of TAVI among
these patients.15,24,25 In a recent post-hoc analysis of the PARTNER
trial, 2-year mortality was significantly reduced (HR 0.43, P ¼ 0.04)
with TAVI when compared with medical management among the
subset of patients (n ¼ 42) with low flow (LF), low LVEF (LEF), and
low gradient (LG) from the inoperable B cohort.15 In addition,
there were no significant differences in 2-year mortality rates
between TAVI and SAVR among the subset of LF LEF LG patients
(n ¼ 105) in the high-risk A cohort (HR 1.25, P ¼ 0.50).15
However, in the latter cohort, an early hazard associated with
SAVR among LF patients was observed, that persisted to 6 months
Figure 5 Changes in left-ventricular ejection fraction (LVEF) over time among patients with an LVEF ≤40%, comparing patients with a mean gra-
dient ≤40 mmHg at baseline [low-flow, low-gradient group (LEF-LG): red dashed line] with patients with a mean gradient .40 mmHg at baseline
[low-flow, high-gradient group (LFHG); dark blue dashed line].
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Table 6 Comparison of post-procedural valvular haemodynamics and patient–prosthetic mismatch between groups
All patients (n 5 307) HGAS (n 5 179) PLF-LG (n 5 77) LEF-LG (n 5 51) P-value
Post-procedural valvular haemodynamics
Aortic valve area, cm2 1.89+0.55 1.92+0.55 1.83+0.49 1.91+0.64 0.494
Indexed aortic valve area, cm2 m22 1.06+0.31 1.08+0.30 1.02+0.27 1.08+0.36 0.356
Mean gradient, mmHg 8.77+3.96 9.40+4.23 8.37+3.39 7.18+3.22 0.001
Patient–prosthetic mismatch grade 0.694
None (iAVA .0.85 cm2 m22) (%) 225 (73) 135 (75) 54 (70) 36 (71)
Moderate (iAVA ≥0.65–0.85 cm2 m22) (%) 76 (25) 41 (23) 22 (29) 13 (25)
Severe (iAVA ,0.65 cm2 m22) (%) 6 (2) 3 (2) 1 (1) 2 (4)
Depicted are means+ SD with P-values from ANOVAs or counts (%) with P-values from x2 tests. n ¼ 47 patients data missing.
iAVA, indexed aortic valve area.
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(relative risk 0.60,P ¼ 0.04) but was no longerapparent at1 year.The
observations made in this study further support the concept of TAVI
as a viable therapeutic option among these high-risk patients and can
be summarized as follows: first, TAVI can be safely performed in
LEF-LG patients. Despite being at significantly higher risk compared
with HGAS patients (logistic EuroSCORE HGAS: 20.9% vs.
LEF-LG: 38.0%, P, 0.001), LEF-LG patients had similar 30-day and
1-year overall mortality rates compared with lower-risk PLF-LG
and HGAS patients. However, LEF-LG patients were at high-risk of
cardiac death at 1 year. Therefore, the post-procedural medical man-
agement of these patients is important and therapeutic strategies
aimed at reducing cardiovascular mortality among this subgroup
shouldbe identified. Secondly, LEF-LGpatientshaveaveryhigharter-
ial afterload despite a low systolic arterial pressure and therefore a
normal or low blood pressure reading should not be thought of as
equivalent to a normal vascular load among these patients. Thirdly,
the majority of patients surviving TAVI exhibited functional improve-
ment at 1 year. Finally, among patients undergoing echocardiographic
follow-up, a significant improvement in LVEF was observed following
TAVI, although the improvement in LVEF was less in LEF-LG patients
whencomparedwith LEF-HGpatients.Thismayhavebeen related to
a lack of contractile reserve among a proportion of LEF-LG patients.
Further studies are required to assess the impact of the presence or
absence of contractile reserve on clinical outcomes among this
patient cohort following TAVI. In addition, whether the residual ar-
terial afterload remains higher among LEF-LG patients compared
with LEF-HG patients following TAVI is unclear. This may be import-
ant as a higher residual arterial afterload may have implications for
post-procedural LVEF improvement. Finally, the overall incidence
of PPM was 27%, which was lower than that reported by Jilaihawi
et al. (32%)29 and Tzikas et al. (39%)30 in a TAVI population. Among
SAVR patients, Mohty et al.31 reported that moderate-to-severe
PPM was an independent predictor of late mortality among those
with a pre-operative LVEF,50%. In addition, Kulik et al.32 reported
that PPM (iAVA ≤0.85 cm2 m22) had an adverse impact on long-
term outcomes among LEF-LG patients undergoing SAVR. In the
present study, we found no association between moderate–severe
PPM and overall mortality at 1 year among LEF-LG patients undergo-
ing TAVI. Further studies are required to compare the impact of PPM
on clinical outcomes among low LVEF patients undergoing TAVI and
SAVR.
Limitations
First, this study reflects the experience of a single centre only.
However, to the bestof our knowledge, this is the first study compar-
ing the invasive haemodynamic characteristics among different
subsets of patients with low-gradient AS undergoing TAVI. Secondly,
use of the estimated VO2 for cardiac output calculation has been
shown to lead to both over- and underestimation of cardiac output
and therefore of SVI and AVA measurements. It has been shown
that estimates of VO2 based on body size significantly overestimated
AVA among elderly patients.33 Therefore in the present study, it is
possible that patients may have had their AVA overestimated. In add-
ition, Gertz et al.33 found that invasive measurements of directly mea-
sured VO2 AVAs were less congruent with three-dimensional
echocardiography in low-flow states, which may have implications
for the present study. Aortic valve gradients were measured by pull-
back technique and not by simultaneous measurement of LV and
aortic pressures, which is considered optimal. The Gorlin constant,
which is assumed to be ‘1’ for aortic tricuspid valves, may contain in-
herent inaccuracies when calculating AVAs using the Gorlin formula.
Importantly, the flow dependency of the Gorlin equation makes AVA
assessment most inaccurate in low-flow states. Thirdly, the role of
indexing AVA for body size is controversial.34 However, we chose
an iAVA ≤0.6 cm2 m22 as a cut-off criterion in order to rule out
small body size as a potential cause of a low gradient in the presence
of a small AVA and preserved LVEF.27 Fourthly, although the haemo-
dynamic and clinical data were prospectively collected, this is a retro-
spective study and therefore may be subjected to confounding
factors. Fifthly, because this is an invasive haemodynamic study, the
findingsmaynotnecessarily beconcordantwith anechocardiograph-
ic study.34 As a result, only patients who underwent a pre-procedural
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Table 7 All-cause mortality at 1-year among patients with and without patient–prosthetic mismatch
PPM
(iAVA ≤0.85 cm2 m22)
No PPM
(iAVA >0.85 cm2 m22)
HR (95% CI) P-value P-value
interactiona
All patients n ¼ 82 n ¼ 225
All cause death, n (%) 13 (19.3) 27 (15.2) 1.27 (0.65–2.46) 0.48
Stratified analysis 0.88
HGAS n ¼ 44 n ¼ 135
All cause death, n (%) 6 (16.5) 15 (13.6) 1.21 (0.47–3.12) 0.69
PLF-LG n ¼ 23 n ¼ 54
All cause death, n (%) 5 (24.8) 7 (17.7) 1.50 (0.48–4.73) 0.49
LEF-LG n ¼ 15 n ¼ 36
All cause death, n (%) 2 (18.2) 5 (18.5) 0.92 (0.18–4.73) 0.92
Depicted are counts (incidence rates %).
Hazard ratios (HR) [95% confidence intervals (CI)] from Cox regressions for time-to-event data, testing PPM vs. no PPM.
aP-value interaction PPM × patient group, decrease of freedom ¼ 2; n ¼ 47 patients data missing.
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right and left heart catheterization with aortic valve crossing were
included in the present analysis and therefore this is not a consecutive
patient series. However, no significant differences in baseline charac-
teristics or clinical outcomes between included and excluded
patients were observed (data not shown). Finally, because only a
small proportion of patients underwent dobutamine stress echocar-
diography, we were unable to stratify LEF-LG patients according to
the presence or absence of flow reserve.
Conclusions
Patients presenting with PLF-LG and LEF-LG had overall mortality
rates comparable with HGAS patients. LEF-LG patients, however,
were more likely to die of cardiac causes and therefore therapeutic
measures aimed at reducing cardiovascular mortality among these
patients following TAVI should be identified. Most surviving patients
demonstrated functional improvement regardless of AS subtype.
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